Saint Luke’s Mid America Heart Institute & AstraZeneca Initiates Phase III DARE-19 Trial with Farixga in COVID-19 Patients

Saint Luke’s Mid America Heart Institute & AstraZeneca Initiates Phase III DARE-19 Trial with Farixga in COVID-19 Patients

AstraZeneca and Saint Luke’s Mid America Heart Institute have initiated a randomized, global Phase III trial to assess the potential of Farxiga (dapagliflozin) as a treatment in patients hospitalized with COVID-19 who are at risk of developing serious complications,...

Pin It on Pinterest